Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alan Vu, Caden Ulschmid & Kenneth B. Gordon. (2022) Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opinion on Biological Therapy 22:12, pages 1489-1502.
Read now
Read now
Fabiola Atzeni, Cesare Siragusano, Ignazio Francesco Masala, Antonio Carriero, Valentina Picerno & Salvatore D’Angelo. (2022) IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?. Expert Opinion on Biological Therapy 22:7, pages 843-853.
Read now
Read now
Articles from other publishers (7)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo & Alessandra Narcisi. (2023)
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study –
IL PSO
(
ITALIAN LANDSCAPE PSORIASIS
)
. Journal of the European Academy of Dermatology and Venereology 37:5, pages 1017-1027.
Crossref
Crossref
Xiaojing Huang, Haojie Shentu, Yujing He, Haijia Lai, Chen Xu, Meiling Chen & Haowei Zhu. (2023) Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunologic Research.
Crossref
Crossref
Chrong-Reen Wang & Hung-Wen Tsai. (2023) Seronegative spondyloarthropathy-associated inflammatory bowel disease. World Journal of Gastroenterology 29:3, pages 450-468.
Crossref
Crossref
Michaela Koehm, Tanja Rossmanith, Ann C Foldenauer, Eva Herrmann, Jan Brandt-Jürgens, Gerd R Burmester, Herbert Kellner, Uta Kiltz, David M Kofler, Jürgen Rech, Sorwe Mojtahed-Poor, Christin Jonetzko, Harald Burkhardt, Frank Behrens, Rieke H.E. Alten, Karolina Benesova, Raoul Bergner, Jürgen Braun, Winfried Demary, Stephanie Finzel, Peter Kästner, Arnd Kleye, Klaus Krüger, Gabriele Lorenz, Regina Max, Denis Poddubnyy, Andrea Rubbert-Roth, Holger Schwenke, Maren Sieburg, Diamant Thaci, Astrid Thiele, Reinhard E. Voll, Ulrich von Hinüber, Jochen Walter & Siegfried Wassenberg. (2023) Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. The Lancet Rheumatology 5:1, pages e14-e23.
Crossref
Crossref
Samar Abdalhamed Tabra, Salwa Elmorsy abd Elghany, Reham A. Amer, Mohamed H. Fouda & Mohammed Hassan Abu-Zaid. (2022) Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clinical Rheumatology 41:11, pages 3391-3399.
Crossref
Crossref
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori, Sebastiano Buti, Matteo Bauckneht, Silke Gillessen, Giuseppe Luigi Banna & Giuseppe Fornarini. (2022) Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers 14:5, pages 1245.
Crossref
Crossref
Zheng Liu, Jun-Yu Zhang, Yun-Jie Yang, Kun Chang, Qi-Feng Wang, Yun-Yi Kong & Bo Dai. (2022) High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. Asian Journal of Andrology 24:2, pages 147.
Crossref
Crossref